Picture of Inhibikase Therapeutics logo

IKT Inhibikase Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapNeutral

Inhibikase Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

* Inhibikase Therapeutics Inc  IKT.OQ  reported a quarterly
adjusted loss of 65 cents​​ per share for the quarter ended
September 30, higher than the same quarter last year, when the
company reported EPS of -86 cents.  The mean expectation of
two analysts for the quarter was for a loss of 37 cents per
share. Wall Street expected results to range from -68 cents
to -6 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Inhibikase Therapeutics Inc's reported EPS for the quarter
was a
loss of 65 cents​.
    * The company reported a quarterly loss of $5.78 million.
    * Inhibikase Therapeutics Inc shares had risen by 86.2% this
quarter and gained 90.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 49% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Inhibikase
Therapeutics Inc is 6.50 
This summary was machine generated from LSEG data November 14 at
08:57 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.37          -0.65          Missed
 Jun. 30 2024      -0.67          -0.66          Beat
 Mar. 31 2024      -0.79          -0.73          Beat
 Dec. 31 2023      -0.85          -0.64          Beat

Recent news on Inhibikase Therapeutics

See all news